RRPV #RAPID_Coming-Soon

BARDA Rapid Antigen and Protein Reagent Development Program Announcement

This opportunity from the Biomedical Advanced Research and Development Authority (BARDA), through the Rapid Response Partnership Vehicle (RRPV), seeks to accelerate the development and production of antibodies and protein-based reagents for diagnostic use. - Government Buyer: - Biomedical Advanced Research and Development Authority (BARDA) - Program managed via the Rapid Response Partnership Vehicle (RRPV) - Products/Services Requested: - Integrated solutions for rapid, end-to-end development and production of antibodies and molecular recognition reagents - Focus on diagnostic applications, including discovery, scalable workflows, and GMP-compatible production - Unique/Notable Requirements: - Solutions must enable rapid delivery of purified, assay-ready reagents within weeks from target identification - High-affinity, high-specificity binder generation against priority targets is required - Scalable, flexible workflows suitable for routine and emergency public health needs - Clear pathway to GMP-compatible production - No specific OEMs or vendors are named in the announcement - Objective is to establish a flexible, deployable capability for timely diagnostic reagent development in response to emerging public health threats

Description

BARDA, through the RRPV, will soon release a new program aimed at accelerating the end-to-end development and production of antibodies and other protein-based molecular recognition reagents for diagnostic applications. The program seeks integrated solutions that significantly reduce traditional development timelines, enabling rapid delivery of purified, assay-ready reagents within weeks from target identification. Proposed approaches must demonstrate high-affinity, high-specificity binder generation and scalable workflows suitable for diagnostic use, with a pathway toward GMP-compatible production. The objective is to establish a flexible capability adaptable to emerging public health threats for timely diagnostic reagent development.

View original listing